SEC Form 4 · accession 0000930413-17-003653
ENZO BIOCHEM INC · ENZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barry W Weiner
Officer — President, CFO, Treasurer, PAO · Director
Period of report
Oct 25, 2017
Accepted (ET)
Oct 27, 2017 · 5:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000316253
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 25, 2017 | M | 112,500 | $3.00 | A | 1,423,367 | D | |
| Common StockF1,F3 | Oct 25, 2017 | S | 54,126 | $10.11 | D | 1,369,241 | D | |
| Common StockF2,F3 | Oct 25, 2017 | F | 33,449 | $10.11 | D | 1,335,792 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (to acquire common stock) | $3.00 | Oct 25, 2017 | M | 112,500 | D | Nov 26, 2014 | Nov 26, 2017 | Common Stock | 112,500 | 215,596 | D |
Explanation of responses
- F1Represents shares sold to satisfy reporting person's tax obligations.
- F2Represents shares withheld by the company to cover the exercise price of the Stock Options.
- F3The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.03 to $10.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.